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The Chinese attenuated equine infectious anemia virus (EIAV) vaccine has successfully protected millions of equine
animals from EIA disease in China. Given that the induction of immune protection results from the interactions
between viruses and hosts, a better understanding of the characteristics of vaccine strain infection and host responses
would be useful for elucidating the mechanism of the induction of immune protection by the Chinese attenuated EIAV
strain. In this study, we demonstrate in equine monocyte-derived macrophages (eMDM) that EIAVFDDV13, a Chinese
attenuated EIAV strain, induced a strong resistance to subsequent infection by a pathogenic strain, EIAVUK3. Further
experiments indicate that the expression of the soluble EIAV receptor sELR1, Toll-like receptor 3 (TLR3) and interferon β
(IFNβ) was up-regulated in eMDM infected with EIAVFDDV13 compared with eMDM infected with EIAVUK3. Stimulating
eMDM with poly I:C resulted in similar resistance to EIAV infection as induced by EIAVFDDV13 and was correlated with
enhanced TLR3, sELR1 and IFNβ expression. The knock down of TLR3 mRNA significantly impaired poly I:C-stimulated
resistance to EIAV, greatly reducing the expression of sELR1 and IFNβ and lowered the level of infection resistance
induced by EIAVFDDV13. These results indicate that the induction of restraining infection by EIAVFDDV13 in macrophages
is partially mediated through the up-regulated expression of the soluble viral receptor and IFNβ, and that the TLR3
pathway activation plays an important role in the development of an EIAV-resistant intracellular environment.Introduction
Equine infectious anemia virus (EIAV) is an equine lenti-
virus with a tropism primary for monocyte/macrophage
lineage in vivo [1,2]. The clinical manifestation of equine
infectious anemia (EIA), which is caused by EIAV infection,
can be divided into an acute phase, a chronic phase, and
an asymptomatic phase. The acute and chronic phases ex-
hibit typical viremia accompanied by a high fever, anemia,
thrombocytopenia, edema, and weight loss. The infected
equines usually enter the life-long asymptomatic carrier
state after 8–12 months. However, the virus maintains a
low level of stable replication in tissues that are enriched* Correspondence: Jianhua_uc@126.com; xjw@hvri.ac.cn
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unless otherwise stated.with monocytes [1,3,4]. Stress or immunosuppression can
increase the EIAV replication level in asymptomatic car-
riers and thus lead to a recurrence of EIA. Because most
EIAV-infected equines become asymptomatic carriers due
to immune control of the infection, EIAV has become a
unique lentivirus model for studies investigating the im-
mune control of lentivirus infection and its pathogenesis.
In addition, most asymptomatic EIAV-infected horses
demonstrate a significant resistance to infections caused by
different pathogenic EIAV strains [1,5]. This finding sug-
gests that the EIAV system can provide a model for study-
ing key immune factors that are involved in resistance to
lentiviral infection, which can be used for the research and
development of preventive lentivirus vaccines.
EIAVFDDV13 is an attenuated EIAV vaccine strain that in-
duces immune protection in approximately 80% of vacci-
nated animals in laboratory and clinical studies [6,7]. An. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion of immune protection imparted by this attenuated
vaccine strain will be useful for elucidating the immune
protective mechanism that is responsible for lentivirus in-
fection. Furthermore, the induction of immune protection
results from the interaction between viruses and hosts.
Therefore, the cellular responses of equine macrophages,
the primary target cells of EIAV in vivo, should be evalu-
ated after being infected by EIAV.
In this study, we examined the infection characteristics
of a pathogenic EIAV strain EIAVUK3 on equine macro-
phages pre-infected by EIAVFDDV3 in vitro. We confirmed
that EIAVFDDV13 induced a strong resistance to the subse-
quent EIAVUK3 infection in equine macrophages. Notice-
ably, in addition to the previously reported mechanism,
i.e. masking viral receptor ELR1 by the SU protein of EIAV
[8,9], our results revealed that up-regulation of the soluble
EIAV receptor and interferonβ (IFNβ) by activated Toll-
like receptor 3 (TLR3) are also largely involved in the re-
sistance to EIAVUK3 infection induced by EIAVFDDV13.
Materials and methods
Cells and viral strains
eMDM and fetal donkey dermal (FDD) cells were used in
this study as target cells for EIAV. The eMDM were pre-
pared from the PBMC of one donor horse. The red blood
cells (RBC) of equine animals have a faster sedimentation
velocity than the white blood cells (WBC) in natural sedi-
mentation in heparinized whole blood without any other
treatment. After at least 30 min natural sedimentation,
RBC will stay in the bottom of the flask, but most WBC in-
cluding monocytes will stay on the upper layer with the
plasma. Thus, the upper plasma layer supernatant including
WBC was obtained from freshly collected, heparinized
whole horse blood following natural sedimentation at room
temperature for 30 min. The blood cells in the supernatant
were isolated with centrifugation at 1000 rpm. After 2–3
washes with cold phosphate-buffered saline (PBS), the cells
were incubated in RPMI 1640 culture medium (Gibco:
Invitrogen Corporation, Carlsbad, CA, USA) supplemented
with 10% horse serum (Hyclone, Logan, USA) and 40%
fetal bovine serum (FBS) (Hyclone) at 37 °C and 5% CO2.
After 24 h of incubation, non-adherent and loosely adher-
ent cells were removed by washing with cold PBS quickly
for three times. The remaining adherent cells were de-
tached with normal saline at 37 °C and seeded into 96-, 24-,
or 6-well microplates (Costar, Corning, USA) for 24 incuba-
tion at 1 × 105, 1 × 106, and 5 × 106 cells/well, respectively,
depending on the experiment. After 48 h incubation, most
adherent cells had differentiated into macrophages (see
Additional file 1 to identify the differentiation from mono-
cytes to macrophages by specific immune-staining) and
were further used for EIAV infection assays. The FDD cell
cultures were prepared and stored in our laboratory. FDDcells were prepared from EIAV negative fetal donkeys and
cultured in minimal essential medium (α-MEM, Gibco)
containing 2 mM L-glutamine, 10% heat-inactivated FBS,
100 IU penicillin, and 100 μg/mL streptomycin (Gibco) as
previously described [10].
Two EIAV strains were used in this study. EIAVFDDV13,
an attenuated vaccine strain of EIAV, was developed by pas-
saging EIAVDLV121, a Chinese donkey leukocyte-adapted at-
tenuated strain of EIAV, in FDD cells for 13 generations. A
protective test demonstrated that EIAVFDDV13 induced pro-
tection from disease in approximately 80% of vaccinated
horses [7], and the strain remained stably attenuated in the
hosts [11]. EIAVUK3, a pathogenic strain of EIAV, is an
infectious clone constructed from the backbone of an
EIAVwyoming strain [12]. This infectious clone was kindly
provided by Dr R. Montelaro of the Center for Vaccine
Research at the University of Pittsburgh. The genomic vari-
ation at the nucleotide level between EIAVFDDV13 and EIA-
VUK3 was approximately 25%.
Quantification of EIAV load and detection of viral replication
Real-time quantitative reverse transcription PCR (RT-
PCR) and reverse transcriptase activity (RT) assays were
used to identify the EIAV load. The relative titers of
EIAVFDDV13 and EIAVUK3 were comparable and consistent
when measured with these methods. Therefore, a quanti-
tative RT-PCR assay of viral genomic RNA was used to
quantify the loads of EIAVFDDV13 and EIAVUK3 according
to previously described procedures [6,13].
The infectious titer of the two EIAV strains was tested
using the median tissue culture infective dose method
(TCID50). Fifty microliters of viral supernatants that were
serially diluted by 10−4, 10−5, 10−6, and 10−7 was added to
eight wells of 96-well flat-bottom plates; each well con-
tained 5 × 105 FDD cells. After an initial incubation of 2 h,
viruses in the culture medium were removed with three
washes with serum-free medium. Fresh cell culture
medium was then added to the cultures, and the infected
cells were incubated continuously. Four days later, EIAV
growth was monitored by measuring viral RT activity using
a Roche RT detection kit (Roche, Basel, Switzerland). Op-
tical density values two-fold higher than those determined
for the negative control were considered to indicate viral
replication. The TCID50 value of the virus was determined
as described by Reed and Muench [14].
To examine the proliferation profiles of EIAV in eMDM,
1 × 105 cells were infected with 1 × 103 TCID50 of
EIAVFDDV13 (amounted to approximately 1 × 10
7 viral RNA
copies of EIAVFDDV13) or 1 × 10
3 TCID50 of EIAVUK3 in a
96-well microplate as indicated in the text. The culture
medium was exchanged for fresh culture medium after 2 h
of infection. The cells in some wells were used to determine
the intracellular viral RNA copies at 3 h after infection by
EIAV. These cells were washed three times with PBS and
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at room temperature for 5 min to remove adherent virus
that had not entered the cells. The other cells that were
used to examine the proliferation profiles were further in-
cubated for 2, 3, 4, 5, 6, or 7 days, after which the cell cul-
ture supernatants were collected. Triplicate wells were
used for each detection time point. Total RNA was ex-
tracted from the harvested cells and culture supernatants
using Trizol (Invitrogen, Carlsbad, CA, USA) or the
QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany)
and was processed for cDNA synthesis using M-MLV re-
verse transcript kit (Invitrogen) using 100 ng of RNA tem-
plate. The cDNA obtained was used for qPCR analysis.
The replication kinetics of the viruses was determined in
three independent experiments.
Co-infection measured by RNA HIS
EIAV positive-strand RNA in infected cells was detected
with a QuantiGene ViewRNA Plate-based Assay Kit
(Panomics, Silicon Valley, USA). Two sets of specific
probes that targeted the EIAV genome at nucleotides 2065
to 3210 of EIAVFDDV13 (GenBank accession # GS00329)
and nucleotides 1,210 to 2356 of EIAVUK3 (GenBank ac-
cession # AF016316) were designed and provided by
Panomics. The divergences between the two targeted re-
gions of these two EIAV strains (EIAVFDDV13 and EIA-
VUK3) are 23.1% and 27.6%, respectively. The eMDM were
plated in 96-well plates (Costar) and simultaneously in-
fected with these two EIAV strains. At 48 h after initial
EIAV infection, the cells were fixed with 4% formaldehyde
and dehydrated in ethanol. During the detection process,
the cells were rehydrated, permeabilized, digested with
protease and hybridized with the specific probes as recom-
mended by the manufacturer. Confocal microscopy and
image acquisition were performed with a Leica TCS SP5
(Leica, Wetzlar, Germany).
Measurement of mRNA expression by the branched DNA
technique and real-time quantitative RT-PCR
The branched DNA (bDNA) technique was used to meas-
ure the expression levels of multiple genes in the cultured
cells. The specific oligonucleotide probe sets for the target
genes included equine TLR3, TLR7, TLR8, TLR9, IFNα1,
IFNβ, ELR1, and β-actin, which were used with the Quan-
tiGene 2.0 Reagent Systems designed and provided by
the manufacturer (Panomics). Information regarding the
probe sets is provided in Additional file 2. The amounts of
multiple target mRNA in each sample were simultan-
eously determined by measuring the wavelengths of color-
coded microspheres and the intensities of the luminescent
emission of streptavidin-conjugated R-phycoerythrin
using a Luminex 200 (Molecular Devices, Silicon Valley,
USA). All data obtained from the Luminex 200 were an-
alyzed using the Luminex IS2.3 program. A total of 100events per region were collected. For all of the samples
analyzed with the bDNA assay, background signals de-
termined in the absence of target mRNA were sub-
tracted from the signals obtained in the presence of
target mRNA. The expression levels of the intracellular
mRNA were normalized to β-actin. Changes in gene ex-
pression were calculated by the following method: fold
changing value = (copies of target mRNA/copies of β-
actin mRNA)treated sample/(copies of target mRNA/copies
of β-actin mRNA)untreated control, and were presented as
the log2 mean fold changing value in the results. The ra-
tio of copies between target mRNA and β-actin mRNA
for the untreated control was used as the calibrator and
assigned a fold-change expression value of 1. Three in-
dependent experiments were performed for each treat-
ment. In addition, the gene expression of the “house-
keeping” β-actin gene used in this study was detected
and compared among different eMDM: those infected
with EIAVFDDV13 and EIAVUK3 or treated with Poly I:C.
The eMDM under different treatments were harvested
at different internal times and counted. eMDM with the
same numbers were used to quantify mRNA copies of
β-actin by Quantitative real-time RT-PCR.
Quantitative real-time RT-PCR using a kit Platinum®
SYBR® Green qPCR SuperMix-UDG (Invitrogen) which
utilizes SYBR Green as a detector was performed by
using an MxPro 3005p qPCR system (Stratagene, La
Jolla, CA, USA) to analyze the expression of ELR-IN, an
alternative splicing isoform of the EIAV receptor ELR1
[15], TLR3, and β-actin. Primers were designed based
on the nucleotide sequence of ELR-IN (GenBank acces-
sion # EF190264) to specifically distinguish ELR-IN
from ELR1. The sequences of the primers were IN-FW,
5′ GGAGAGTCCTTCAGACCTGAGTTCAC3′; IN-RV,
5′ CGCTGCACCTAGGAGAGAAGATTGGC3′. The
primers for TLR3 mRNA (GenBank accession # NM_
001081798.1) were TLR3-FW, 5′ GGGCAAGAACTC
ACAGGTCAG 3′; TLR3-RV, 5′ CAAACCAGGCAAT
GCTTTCAC 3′. The primers for β-actin mRNA were
F2, 5′ CGACATCCGTAAGGACCTGTA 3′; R2, 5′ CA
TCTGCTGGAAGGTGGACAA 3′. Total RNA was ex-
tracted from the harvested cells using Trizol (Invitrogen)
and was processed for cDNA synthesis using an M-MLV
reverse transcript kit (Invitrogen,) using 100 ng of RNA
template. The cDNA obtained was used for qPCR analysis.
qPCR was conducted under the following conditions sug-
gested by the manufacturer of Platinum SYBR Green
qPCR SuperMix-UDG kit (Invitrogen): initial preincuba-
tion at 50 °C for 20 s; 95 °C for 10 min; 40 cycles of 95 °C
for 30 s and 60 °C for 1 min; and one cycle of 95 °C for
1 min, 55 °C for 30 s and 95 °C for 30 s for signal sam-
pling. Linear regression analysis of the standard curve
and the β-actin values was used to estimate the ELR-IN
and TLR3 mRNA level in the samples.
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Enzyme-linked immunosorbent assays (ELISA) for the
analysis of equine IFNα and IFNβ proteins were per-
formed as described in the protocol provided by the
manufacturer (Uscn Life Science, Wuhan, China). The
plate was read with a microplate reader VERSAmax
(Molecular Devices). The protein expression levels of IFN
were measured by ELISA as pg/mL calibrated with a set of
standards provided by this kit, and the changes in protein
expression levels in each sample were calculated using the
following formula: fold changing value = the amount of
target protein in the treated samples/the amount of target
protein in untreated samples, and the mean values of fold
change were converted to log2. The amount of IFN pro-
teins in the untreated control was used as the calibrator
and assigned a fold-change expression value of 1. All reac-
tions were performed in triplicate.
EIAV infection of poly I:C-treated eMDM
eMDM were cultivated in 96-well plates and treated with
either 0.5 μg/mL poly I:C (Sigma-Aldrich, St Louis, USA)
or the same volume of PBS as a control. The culture
supernatant was removed 12 h after the treatment, and
fresh medium was added. The cells were then infected
with 1 × 103 TCID50 of EIAVUK3. After 2 h of incubation,
the culture medium was removed, and the cells were
washed three times with PBS before incubation in fresh
medium for an additional 72 h. The viral copy numbers in
the culture medium of triplicate wells were quantitatively
analyzed by qPCR.RNA interference of TLR3 expression
To knock down TLR3 expression, a TLR3-specific small
interfering RNA (siRNA-TLR3) and a control siRNA
(siRNA-C) with scrambled sequences were synthesized by
RiboBio, Guangzhou, China. The target sequence was 5′-G
GACCTTGGCCTTAATGAA-3′, and the product number
for siRNA-C was Ncontrol_05815. Primary eMDM were
plated in 96-well plates at 1 × 105/well and transfected with
either 50 nM siRNA-TLR3 or 50 nM siRNA-C using the
transfection reagent FuGENE HD (Promega, Madison,
USA) according to the manufacturer’s protocol. The cells
were harvested at 48 h after transfection and evaluated for
the efficacy of TLR3 mRNA knockdown.Statistical analysis
All experiments in the present study were replicated at
least three times unless specifically indicated. The results
in the figures are presented as the mean ± SEM. Signifi-
cant differences between samples or groups were deter-
mined with the student’s t-test. The statistical analysis
was performed using SAS 8.1 software.Results
EIAVFDDV13 induced strong resistance to the infection of
EIAVUK3 on eMDM
To examine the ability of EIAVFDDV13 to interfere with
the infection of EIAVUK3, a pathogenic EIAV strain,
EIAVFDDV13 and EIAVUK3 viruses at the same infectious
titer were first used to infect equal numbers of eMDM
The infection and replication patterns of the two strains
were analyzed with qRT-PCR. The intracellular viral
copy numbers determined in early-phase infection
(3 hours post-infection (hpi)) indicate that the number
of viruses that entered the cells was similar for the two
strains (Figure 1A). The co-presence of both EIAVFDDV13
and EIAVUK3 in infected cells was examined by View-
RNA in situ hybridization using probes labeled with dif-
ferent fluorescent dyes. The images of EIAV in infected
cells presented in Figure 1B clearly demonstrate that
these two viral strains co-infected and replicated in com-
mon macrophages. Furthermore, the replication kinetics
of EIAVFDDV13 and EIAVUK3 in the cell culture medium
during the seven-day post-infection period was exam-
ined using inocula normalized by either TCID50 or RNA
copy numbers. Besides a slight decreased viral load of
EIAVFDDV13 on 4 days post infection (dpi), the two EIAV
strains grew equally well in cultivated eMDM with simi-
lar replication kinetics regardless whether initially normal-
ized by infectivity or viral particles (Figure 1C). In addition,
the difference in the ratio of RNA copy number/infectious
titer in the viral stocks, which represents the difference in
infectivity of EIAV in the target cells [16], was measured.
The measured ratios for EIAVFDDV13 and EIAVUK3 were
33 133.73 ± 2204.662 and 29 245.28 ± 2037.972, respectively,
with no significant difference (P = 0.14). These results indi-
cate that the two EIAV strains used in this study replicated
in eMDM with similar kinetics and similar cell-cell spread-
ing efficacies.
Afterwards, the restriction of a subsequent infection
with EIAVUK3 by pre-infection with EIAVFDDV13 or a sub-
sequent infection with EIAVFDDV13 by pre-infection with
EIAVUK3 was investigated. The viral RNA copy numbers
of EIAVUK3 or EIAVFDDV13 in eMDM pre-infected with
EIAVFDDV13 for 6, 12, 24, 36 and 48 h were measured and
compared with the EIAV RNA copy numbers in control
groups (cells not treated with pre-infection of EIAV). As
shown in Figure 1D, the RNA copy numbers of EIAVUK3
were markedly reduced by 92.68 ± 3.35% by prior infection
with EIAVFDDV13 for 6 h compared with the control
group. The restriction effect increased by approximately
5-fold with prolonged pre-infection time until 24 h, at
which point the reduction in RNA copy number was
98.71 ± 0.48%. In contrast, the resistance induced by EIA-
VUK3 to subsequent infection by EIAVFDDV13 was much
weaker. The restriction induced by EIAVUK3 was approxi-
mately 85% throughout the detection period and was 10-
Figure 1 EIAVFDDV13 induced strong resistance to subsequent infection of EIAVUK3 in eMDM. (A) Comparison of intracellular viral levels in
the early phase of infection. The same infectious dose (1 × 103 TCID50/well) of the attenuated EIAV strain EIAVFDDV13 and the pathogenic strain
EIAVUK3 was used to infect eMDM in 96-well microplates. At 3 hpi, the copy numbers of intracellular EIAV RNA were measured with qPCR.
(B) Co-infection of eMDM with EIAVFDDV13 and EIAVUK3. Cultivated eMDM were simultaneously infected with equivalent TCID50 of EIAVFDDV13 and
EIAVUK3. Intracellular viruses were detected with ViewRNA in situ hybridization at 48 hpi and are indicated as fluorescently labeled granules (red
for EIAVFDDV13 and green for EIAVUK3). (C) Comparison of the replication kinetics of EIAVFDDV13 and EIAVUK3 in eMDM. Stocks of these two viruses
with an equal TCID50 or equal RNA copy numbers were used to infect eMDM as indicated. Viruses in the culture medium were quantified as viral
RNA copy numbers at various time points up to 7 dpi. (D) Quantitative analysis of the restriction of EIAVUK3 or EIAVFDDV13 infection by prior
EIAVFDDV13 or EIAVUK3 infection. Cultivated eMDM were pre-infected by 1 × 10
3 TCID50 of EIAVFDDV13 or EIAVUK3 in 96-well plates. The culture
medium was changed after 2 h of infection. The cells were washed three times with PBS at 6, 12, 24, 36 and 48 hpi and were infected with
equivalent infectious amounts of EIAVUK3 or EIAVFDDV13 diluted in the culture medium. After another 48 h, the culture supernatant was collected
and the viral loads of the subsequently infected virus in the medium were measured as the copy numbers of EIAV RNA. The Y-axis of the graph
represents the ratio of viral RNA copies to the number of viral RNA copies in cells without pre-infection with EIAV.
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of pre-infection. Meanwhile, there was no significant dif-
ference in apoptosis of eMDM induced by the infection ofthese two EIAV strains (see Additional file 3), which ruled
out the possible effect of cell degradation on the afore-
mentioned difference in viral RNA replication. These
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in eMDM induced a strong resistance to the subsequent in-
fection of EIAVUK3.
Infection of eMDM with EIAVFDDV13 and EIAVUK3
differentially influenced the expression of ELR1 and
soluble ELR1 (sELR1)
The EIAV receptor ELR1 has been shown to play an im-
portant role in induction of superinfection resistance
(SIR) [9]. To investigate the role of ELR1 in the infection
resistance induced in eMDM by EIAVFDDV13, a quantita-
tive analysis of ELR1 mRNA levels in eMDM up to 36
hpi with EIAVFDDV13 was performed. As a provirus-
derived pathogenic strain, the inductive activity of EIA-
VUK3 was also investigated to compare it with that of
EIAVFDDV13. As shown in Figure 2A, the kinetics of
ELR1 mRNA expression was similar in eMDM infected
with the two viruses: ELR1 expression was first down-
regulated and then up-regulated. However, both down-
regulation and up-regulation occurred over a limited
range, and down-regulation only occurred within 6 hpi,
suggesting a limited involvement of ELR1 regulation in
EIAV-induced infection resistance. Meanwhile, β-actin
expression in eMDM was not influenced after being in-
fected with EIAVFDDV13 and EIAVUK3 (see the result in
Additional file 4). It ensured the validity of the data for
gene expression dynamics obtained in this study.
We recently identified an alternative splicing variant of
ELR1 transcripts that retained a fragment of intron 6. This
sliced transcript, termed as ELR-IN (GenBank accession #
EF190264), accounts for a large proportion of ELR1 tran-
script variants (approximately 50% of the ELR1 transcript)
and creates an isoform with four different amino acid resi-
dues and then a premature stop codon 14 residues up-
stream of the predicted membrane spanning domain. TheFigure 2 Regulation of membrane-bound and soluble EIAV receptor e
membrane-bound EIAV receptor ELR1 expression. Total RNA was extracted
EIAVFDDV13 or EIAVUK3 for various times. ELR1 mRNA was quantified with a b
expression. ELR-IN is a transcriptional variant of ELR1 that encodes a soluble
infected with either EIAVFDDV13 or EIAVUK3 for various times were quantified
*P < 0.05, **P < 0.01.truncated ELR1 protein is predicted and confirmed as a
soluble form of ELR1. A separate study revealed that
sELR1 appeared to inhibit EIAV infection in cultivated host
cells [15]. Therefore, the regulation of ELR-IN expression
by EIAV infection was tested. The levels of sELR1 mRNA
in eMDM infected with EIAVFDDV13 were significantly
higher than in EIAVUK3-infected cells and uninfected con-
trol cells within 12–24 h after infection, differently than
that was observed for transmembrane ELR1 (Figure 2B).
This result suggests that the up-regulation of sELR1 ex-
pression in eMDM after infection with EIAVFDDV13 may
contribute to induction of infection resistance by this
EIAV strain.The expression levels of viral nucleic acid-recognizing TLR
and type I interferons were differentially regulated by
EIAVFDDV13 and EIAVUK3 infection in eMDM
Because macrophages, the primary target cells of EIAV
in vivo, are important in immune responses and are essen-
tial for the effects of TLR activation on the innate anti-
virus mechanisms of immunocytes, the activation of
TLR3, TLR7, TLR8 and TLR9, which are activated by
single-stranded or double-stranded foreign RNA or for-
eign DNA, was analyzed. As shown in Figure 3A,
EIAVFDDV13 significantly up-regulated TLR3 mRNA ex-
pression, with a peak (8- to 10-fold) at 24 hpi. However,
EIAVUK3 had no effect on TLR3 mRNA levels. With
regards to TLR7 and TLR8 expression, EIAVUK3 up-
regulated TLR expression approximately 0.5- to 1.5-fold at
12 to 24 hpi, but EIAVFDDV13 did not exhibit such an ef-
fect. No significant difference in TLR9 expression was ob-
served in eMDM infected with EIAVFDDV13 and EIAVUK3;
both strains moderately up-regulated TLR9 expression
(see Additional file 5).xpression in eMDM by EIAVFDDV13 and EIAVUK3. (A) Regulation of
from eMDM that were infected with equal infectious titers of either
ranched DNA (bDNA) assay. (B) Regulation of soluble EIAV receptor
form of the receptor (sELR1). The expression levels of ELR-IN in eMDM
with real-time qPCR. The values of Y axis were treated by Log2.
Figure 3 Regulation of TLR3 and IFNβ expression in eMDM by EIAVFDDV13 and EIAVUK3. eMDM infected with equal infectious titers of either
EIAVFDDV13 or EIAVUK3 for various times were selected. Some cells were treated with Trizol, and the total RNA was extracted to quantify TLR3 (A)
and IFNβ (B) mRNA expression with the bDNA assay. The remaining cells were lysed with RIPA cell lysis buffer, and the protein levels of IFNβ in
the eMDM lysates were measured with an ELISA kit (C). The values of Y axis were treated by Log2. **P < 0.01.
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ated with intracellular TLR activation and that they are
part of the downstream products of TLR signaling path-
ways [17-19]. Given the obvious up-regulation of TLR3
mRNA expression by EIAVFDDV13 infection and the anti-
viral activity of type I interferons, changes in the expres-
sion of IFNβ and IFNα in eMDM after infection with
EIAVFDDV13 and EIAVUK3 were evaluated. As shown in
Figure 3B, there were significant differences in IFNβ ex-
pression in eMDM infected with the two strains. At 24 h
after the infection of eMDM with EIAVFDDV13, IFNβ ex-
pression was up-regulated by 10- to 20-fold at the
mRNA level and 4- to 6-fold at the protein level com-
pared with the mock-treated control; the timing of this
up-regulation was correlated with the temporal up-
regulation of TLR3 expression in eMDM infected with
EIAVFDDV13. In contrast, IFNβ mRNA and protein expres-
sion in eMDM infected with EIAVUK3 did not differ signifi-
cantly from those in the mock-treated control. Although
EIAVUK3 infection up-regulated IFNα expression (approxi-
mate 3 folds in protein level), infection with EIAVFDDV13
basically did not (Additional file 6). Based on the antiviral
effect of IFNβ, it is likely that the up-regulation of IFNβexpression is positively correlated with the strong infection
resistance induced by EIAVFDDV13.
TLR3 activation in eMDM induced by poly I:C resulted in
increased sELR1 and IFNβ mRNA expression
Considering the correlation between strong induction of
infection resistance and elevated TLR3 and IFNβ expres-
sion induced by attenuated EIAVFDDV13 as well as the ex-
istence of a signaling pathway linking TLR3 activation
with IFNβ expression, the effect of TLR3 activation on in-
fection resistance induced by EIAVFDDV13 was mimicked
by treating eMDM with poly I:C, a TLR3 ligand. Treat-
ment with poly I:C at 0.5 μg/mL up-regulated TLR3
mRNA expression to similar levels as those observed in
eMDM infected with EIAVFDDV13 (Figure 4A). In addition,
replication of the pathogenic EIAV strain EIAVUK3 in poly
I:C-treated cells declined by approximately 90% compared
with untreated cells (Figure 4B). By the way, β-actin ex-
pression was at a similar level in eMDM after being
treated with poly I:C or being infected with the two EIAV
strains used in this study (see Additional file 4). This could
also ensure the validity of the data for gene expression dy-
namics obtained in this experiment.
Figure 4 Effects of poly I:C on TLR3, type I interferons and sELR1 expression and EIAV replication. (A) Effects of poly I:C on TLR3, IFNβ
and sELR1 expression. eMDM were treated with poly I:C (0.5 μg/mL) for 12 h. The expression levels of specific mRNA in the cells were analyzed
using the bDNA assay. The values of Y axis were treated by Log2. (B) Effects of poly I:C on EIAVUK3 replication. eMDM were treated with either
0.5 μg/mL poly I:C or the same volume of PBS as a control for 12 h; the cells were then infected with EIAVUK3. Viral RNA copy numbers in the
culture medium were measured with real-time qPCR at 72 hpi. *P < 0.05.
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poly I:C in eMDM, the mRNA expression levels of both
IFNβ and sELR1 were up-regulated. The up-regulation of
IFNβ was similar to that observed in EIAVFDDV13-infected
eMDM (Figure 4A). Moreover, expressions of IFNα and
TLR7-9, which show lower intensity induced by attenu-
ated EIAVFDDV13 than that induced by the virulent EIA-
VUK3 or show a limited difference between these two
EIAV strains, were also not up-regulated after poly I:C
treatment (data not shown). These results indicate that
enhanced IFNβ and sELR1 expression can be induced by
TLR3 activation, which in turn promotes resistance of the
target cells to EIAV infection.
TLR3 activation in eMDM played an important role in
induction of infection resistance to EIAVUK3
To confirm that up-regulated TLR3 expression plays a cru-
cial role in the induction of infection resistance in
EIAVFDDV13-infected eMDM, TLR3 expression in eMDM
was knocked down with siRNA. As shown in Figure 5A,
TLR3 transcription was reduced by approximately 65% in
eMDM transfected with horse TLR3 siRNA (siRNA-TLR3)
compared with cells transfected with scrambled RNA con-
trol siRNA-C. When the siRNA-TLR3-transfected cells
were treated with 0.5 μg/mL poly I:C for 12 h, only a slight
up-regulation of TLR3 mRNA expression (0.5-fold) was
observed, whereas an approximately 8.0-fold increase in
TLR3 mRNA expression was detected in siRNA-
C-transfected cells (Figure 5B). These results indicate
that TLR3 expression was substantially suppressed by
its specific siRNA. The effect of EIAVFDDV13 on TLR3,
sELR1 and IFNβ expression was evaluated after TLR3
knockdown. As shown in Figure 5C, compared with theeffect of EIAVFDDV13 on eMDM that were not treated
with siRNA, the up-regulation of these three factors
was greatly diminished in cells transfected with specific
siRNA-TLR3.
Furthermore, to determine whether the inhibitory ef-
fects of poly I:C on EIAV replication and infection re-
sistance induced by EIAVFDDV13 infection in eMDM
were reduced after TRL3 knockdown, the viral copy
numbers of EIAVUK3 in siRNA-TLR3-transfected,
siRNA-C-transfected and untransfected eMDM were
analyzed after stimulation with poly I:C, and the induc-
tion of infection resistance by EIAVFDDV13 was evalu-
ated in siRNA-TLR3-transfected eMDM. As shown in
Figure 6A, the TLR3 ligand poly I:C induced an ap-
proximately 90% reduction of the growth of EIAVUK3 in
equine macrophages, but failed to effectively inhibit the
viral replication in the cells that had been transfected
with siRNA-TLR3. More importantly, TLR3 knockdown
reversed the inhibition induced by EIAVFDDV13 to the
level of 6 h of pre-infection (Figure 6B).
Discussion
In this study, we found that in equine macrophages,
EIAVFDDV13 infection could induce strong resistance to
subsequent infection of the heterologous virulent EIAV
strain EIAVUK3. Furthermore, we observed that some
cellular factors involved in the activation of innate im-
munity by EIAVFDDV13, which occurred primarily
through TLR3 activation, were important contributors
to the development of infection resistance. Such host
cell responses could disturb either the entrance or rep-
lication of the virus, which results in the decline of
viral RNA copies in target cells. As observed in this
Figure 5 Effects of TLR3 mRNA knockdown on sELR1 and INFβ expression in eMDM. (A) Knockdown of TLR3 expression in eMDM with
siRNA. At 48 h after transfection with siRNA targeting equine TLR3 (siRNA-TLR3), the expression level of TLR3 mRNA was quantified with real-time
qPCR. siRNA with a scrambled sequence (siRNA-C) was used as the control. (B) The induction of TLR3 expression by poly I:C in siRNA-TLR3-
transfected eMDM. The cells were transfected with siRNA-TLR3 or siRNA-C. TLR3 mRNA was measured with real-time qPCR 12 h after stimulation
with 0.5 μg/mL poly I:C. (C) Kinetics of TLR3, sELR1 and INFβ mRNA expression induced by EIAVFDDV13 in eMDM transfected with siRNA-TLR3. Cells
were transfected with siRNA-TLR3 or siRNA-C. After 48 h of incubation, EIAVFDDV13 was added to the cells, and total RNA was extracted at different
times after infection. The mRNA copies were specifically amplified and quantified with bDNA (for TLR3 and INFβ) and qPCR (for sELR1). The values
of Y axis were treated by Log2. *P < 0.05.
Figure 6 EIAV replication and induction of infection resistance in eMDM after TLR3 mRNA knockdown. (A) The inhibitory effect of poly I:
C on EIAVUK3 replication in eMDM transfected with specific siRNA-TLR3 or control siRNA-C. After transfection with siRNA for 48 h, the cells were
stimulated with 0.5 μg/mL poly I:C for 12 h before infection with EIAVUK3. Viral RNA copies were measured with qPCR at 72 hpi. (B) The effect of
TLR3 mRNA knockdown on the resistance to subsequent viral infection induced by EIAVFDDV13. eMDM transfected with TLR3-specific or control
siRNA were first infected with EIAVFDDV13. The cells were subsequently infected with EIAVUK3 at different times; at 72 h later, the viral RNA copy
numbers of EIAVUK3 in the culture medium were measured with qPCR and compared with the EIAVUK3 RNA copy numbers in eMDM that were
not initially infected with EIAVFDDV13. *P < 0.05, **P < 0.01.
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supernatant of macrophages preinfected with EIAVFDDV13
were noticeably lower than that in the un-preinfected
controls.
The phenomenon that a virally infected cell becomes re-
sistant to subsequent infection by the same or similar vi-
ruses is referred to as superinfection resistance (SIR) [20].
In this study, Figure 1A shows that at least 10 copies of
viral RNA were detected per cell 3 hpi. This level of detec-
tion suggests that every target cell was infected by EIAV
prior to the second infection of EIAVUK3. Therefore, SIR is
one of the possible mechanisms that takes part in the
development of resistance to subsequent viral reinfection.
The primary mechanism underlying SIR induction by
HIV-1 is down-regulation of the expression of the
principle HIV-1 receptor CD4 on the cell surface [20,21].
In the present study, only limited up- or down-regulation
on the mRNA level of EIAV receptor ELR1 was detected
in eMDM infected with either EIAVFDDV13 or EIAVUK3.
This observation is consistent with previous reports that
the amount of membrane-bound ELR1 was not reduced
by EIAV infection [8,9]. In addition, these two EIAV
strains acted similarly on ELR1 expression but induced
TLR3 expression differently, which implicates that ELR1
does not play an essential role in the resistance to subse-
quent infection inducted by EIAVFDDV13. In contrast to in-
tact membrane-bound ELR1, a 2- to 3-fold difference in
the expression of sELR1, the soluble form of ELR1, was
detected after infection of eMDM with EIAVFDDV13, but
not EIAVUK3. Because soluble viral receptors generally
exert inhibitory effects on viral infection [22-24] and
sELR1 mRNA accounts for as much as 50% of the total
ELR1 mRNA present (unpublished data), the changes in
sELR1 expression observed after viral infection in this
study are likely to be involved in the resistance induced by
EIAV. Our results demonstrate that poly I:C stimulated
sELR1 expression by specifically activating TLR3 and that
sELR1 expression was not up-regulated by EIAVFDDV13 in-
fection of eMDM after the knockdown of TLR3 mRNA.
These data support the hypothesis that TLR3 pathway ac-
tivation mediates the up-regulated expression of the sol-
uble ELR1 receptor after EIAV infection. However, one
should be cautious in evaluating the role of sELR1 in
SIR induced by EIAVFDDV13 because of the observed
modest up-regulation of sELR1 mRNA expression and
the absence of confirmation at the protein level, which
was precluded by the low native expression of sELR1 in
eMDM and the lack of a specific antibody that differen-
tiates sELR1 from the prototype ELR1. Beside this, the
linkage between TLR3 activation and sELR1 expression
is not clear.
In addition to the up-regulation of soluble viral recep-
tors, the enhanced expression of innate immunity-related
factors is another mechanism that restrains viralreplication and protects cells from subsequent infection.
In the present study, we focused on TLR3 and IFNβ. Our
results show EIAVFDDV13 strongly stimulated TLR3,
whereas EIAVUK3 did not. TLR3 activation in macro-
phages has been shown to prevent HIV-1 infection [25],
suggesting that the activation of the TLR3 signaling path-
way might help macrophages to resist subsequent infec-
tion with similar viruses. In this study, stimulating TLR3
expression by poly I:C effectively prevented EIAV infection
of the target cells, and TLR3 knockdown with siRNA
largely reduced the antiviral effect of poly I:C. Although
other pattern recognition receptors (PRR), such as retinoic
acid-inducible gene protein I (RIG-I) and melanoma
differentiation-associated protein 5 (MDA-5), belong to
the RIG-I-like receptor (RLR) family and might also be in-
volved in the innate immune response against EIAV infec-
tion, our results indicate that enhancing TLR3 expression
alone effectively improved the ability of macrophages to
resist to EIAVUK3 infection. On the contrary, our results
also show that the resistance to subsequent infected EIA-
VUK3 induced by a TLR3 ligand, poly I:C, was noticeably
lower than that induced by EIAVFDDV13 (90% vs 98% of in-
hibition), and the knockdown of TLR3 expression by
siRNA only reversed 10-20% resistance to the subse-
quently infected virus. Even though the incomplete inter-
ference of TLR3 expression (about 65%) partially counts
for the incomplete reverse of the EIAVFDDV13-induced
SIR, other mechanisms may also be involved in, such as
interfering viral entrance by the binding of EIAV gp90 sur-
face protein to the membrane-bound receptor ELR1 [8,9].
Following TLR3 activation by EIAVFDDV13, IFNβ pro-
duction in eMDM also significantly increased, which was
consistent with IFNβ as a major downstream product of
this PRR [26,27]. Considering the important role of IFNβ
in innate anti-virus function, the significantly up-regulated
IFNβ expression observed in eMDM infected with
EIAVFDDV13 is considered a key contributor in the infec-
tion resistance induced by this virus. In addition to their
role in antiviral function, TLR3 and IFNβ also play import-
ant roles in specific adaptive immune responses. In
addition to their role in antiviral function, TLR3 and IFNβ
also play important roles in specific adaptive immune re-
sponses. These include the promotion of T cell-dependent
and -independent antibody responses in follicular B cells
[28,29], the promotion of germinal center formation, the
production of neutralizing antibodies [30] and the stimula-
tion of the development of lymph node-resident T follicu-
lar helper cells [31]. These activated immunocytes are
critical for the germinal center reaction and humoral
immunity response [32]. Therefore, the enhanced up-
regulation of TLR3 and IFNβ expression induced by
EIAVFDDV13 likely contributes to the development of
specific immunity against EIAV that is elicited in vivo
through the inoculation with the attenuated strain.
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added, which were normalized by both TCID50 and viral
RNA copy number, and these two viruses had similar rep-
lication kinetics and infectivity, EIAVFDDV13 and EIAVUK3
induced significantly different TLR3, sELR1 and IFNβ
expression in eMDM. Our data indicate that besides the
previous reported mechanism of competitive receptor
binding by the viral surface protein, TLR3 pathway activa-
tion plays a vital role in the infection resistance induced
by EIAVFDDV13 infection in macrophages in vitro. There-
fore, these two viral strains should stimulate the dsRNA-
recognizing TLR3 with different efficacies. Because the
sequence variation in the genomes of EIAVFDDV13 and EIA-
VUK3 is approximately 25% [33,34], the dsRNA structures
formed within the single-strained RNA viral genomes are
considered different. In addition, EIAVFDDV13 consists of
quasispecies with an average genomic diversity of approxi-
mately 3% while EIAVUK3 is derived from a proviral clone
[6,12]. These differences may influence the binding affinities
of PAMP (dsRNA) for TLR3 in these two EIAV strains, and
appear to account for the differences in PRR activation and
the expression of TLR3-associated cytokines. Besides the
aforementioned speculation, another aspect under consid-
eration is that the virulent EIAVUK3 may have one or more
mechanisms to block or dampen the early innate immune
response. Exploration of EIAV-specific mechanisms that
are responsible for the suppression of innate immunity by
virulent strains should be highly informative. Consequently,
the results of this study provide insights that will facilitate a
better understanding of the interaction between host cells
and EIAV, as well as other lentiviruses.
Our data demonstrate that sELR1 and IFNβ are up-
regulated when TLR3 is activated and those cells in which
TLR3 is activated show enhanced resistance to EIAVUK3 in-
fection. Silencing TLR3 expression with siRNA significantly
reduces this inhibitory effect. More importantly, infection
resistance induced by EIAVFDDV13 is significantly reversed
after TLR3 silencing. Based on the significant difference in
TLR3 expression in eMDM stimulated with EIAVFDDV13
and EIAVUK3, we hypothesize that TLR3 pathway activation
plays an important role in the induction of infection resist-
ance by EIAVFDDV13 infection in macrophages in vitro.Additional files
Additional file 1: Identification of the differentiation of
macrophages from monocytes. (A) Equine MDM were prepared from
horse PBMC as described in Materials and Methods and were examined
by immunofluorescence assay (IF) using a macrophage specific CD68
mAb. The adherent cells were photographed at 200× magnification. The
irregular cytoplasm (grey arrow) and pseudopodia (black arrow) of
phagocyte morphology were developed and observed at 48 h of
cultivation under white light. Increasing signals of CD68 were detected
by IF (red fluorescence). (B) The adherent cells were infected by
EIAVFDDV13 after 48 of cultivation. Infected cells were detected by indirectIF using an EIA positive serum and a Texas Red-labeled (a red fluorescent
dye) anti-horse IgG mAb 48 hpi.
Additional file 2: mRNA detected by bDNA. The specific
oligonucleotide probe sets for the target genes included equine TLR3,
TLR7, TLR8, TLR9, IFNα1, IFNβ, ELR1, and β-actin, which were used with
the QuantiGene 2.0 Reagent Systems designed and provided by the
manufacturer (Panomics).
Additional file 3: Analysis of the early (Annexin V+/PI−) and late
(Annexin V+/PI+) apoptotic populations of eMDM infected with
either EIAVFDDV13 or EIAVUK3. eMDM infected with either EIAVFDDV13 or
EIAVUK3 for 1, 3, 5 and 8 days were analyzed for apoptosis by flow
cytometry. The eMDM were trypsinized and collected at the indicated
time points and washed once with the Binding Buffer. These cells were
re-suspended in 100 μL Binding Buffer and were stained by adding 5 μL
AnnexinV and 5 μL of 3 μM PI. After 15 min incubation at room
temperature, apoptotic populations were analyzed. Triplicate wells of cells
were examined for each treatment. The results were calculated from the
data of three independent experiments.
Additional file 4: The expression of “house-keeping” gene β-actin
in eMDM infected with EIAV or treated with Poly I:C. Cells were
infected with either EIAVFDDV13 or EIAVUK3 or treated with Poly I:C. The
same amount of cells (1 × 105) from each treatment was harvested and
mRNA copies of β-actin in these cells were quantified by real time
RT-PCR. NC: negative control of untreated cells.
Additional file 5: Regulation of TLR7, TLR8 and TLR9 expression in
eMDM by EIAVFDDV13 and EIAVUK3. Total RNA was extracted from
eMDM infected with equal infectious titers of either EIAVFDDV13 or EIAVUK3
for various times. The mRNA levels of TLR7, TLR8 and TLR9 were
quantified with the bDNA assay. The values of Y axis were treated by
Log2. **P < 0.01.
Additional file 6: Regulation of IFNα expression in eMDM by
EIAVFDDV13 and EIAVUK3. Total RNA was extracted from eMDM infected
with equal infectious titers of EIAVFDDV13 or EIAVUK3 for various times.
mRNA encoding IFNα1 was quantified with the bDNA assay. The protein
expression level of IFNα was measured using an ELISA kit. The values of
Y axis were treated by Log2. *P < 0.05, **P < 0.01.
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